(Q34636081)

English

Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22357255%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22357255%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

0 references

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22357255%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22357255%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Piotr Rutkowski

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22357255%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

author name string

P Reichardt

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22357255%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

H Gelderblom

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22357255%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

M Schlemmer

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22357255%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

G D Demetri

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22357255%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

B Bui-Nguyen

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22357255%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

S Yazji

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22357255%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Y Hsu

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22357255%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

I Galetic

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22357255%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

publication date

21 February 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22357255%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22357255%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

23

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22357255%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22357255%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1680-1687

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22357255%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR598

21 January 2018

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR598

21 January 2018

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR598

21 January 2018

Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sa

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR598

21 January 2018

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR598

21 January 2018

Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR598

21 January 2018

Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR598

21 January 2018

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR598

21 January 2018

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR598

21 January 2018

Preclinical evaluation of nilotinib efficacy in an imatinib-resistant KIT-driven tumor model

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR598

21 January 2018

hOCT 1 and resistance to imatinib

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR598

21 January 2018

Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR598

21 January 2018

Active transport of imatinib into and out of cells: implications for drug resistance

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR598

21 January 2018

Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR598

21 January 2018

Interaction of imatinib mesilate with human P-glycoprotein

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR598

21 January 2018

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR598

21 January 2018

A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR598

21 January 2018

Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR598

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR598

21 January 2018

Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR598

21 January 2018

Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR598

21 January 2018

Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR598

21 January 2018

Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR598

21 January 2018

We should desist using RECIST, at least in GIST.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR598

21 January 2018

RECIST revisited: a review of validation studies on tumour assessment

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR598

21 January 2018

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR598

21 January 2018

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR598

21 January 2018

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR598

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34636081&oldid=2137717416"